Highlights in Stroke in 2025

doi:10.3969/j.issn.1673-5765.2026.01.001

Abstract

Abstract: In 2025, clinical research in cerebrovascular diseases continued to advance amid challenges and opportunities. Global researchers conducted extensive explorations in expanding the boundaries of reperfusion therapy for ischemic stroke, optimizing adjuvant treatment strategies, and advancing precision in secondary prevention. Despite facing setbacks from negative outcomes in areas such as neuroprotection, endovascular treatment for medium vessel occlusion, and rehabilitation therapy, breakthrough progress in adjuvant reperfusion therapy and late-window thrombolysis injected strong momentum into clinical practice of cerebrovascular diseases. This article reviews and interprets key clinical studies in the field of cerebrovascular diseases in 2025, aiming to help readers grasp academic frontiers and track disciplinary developments through a synthesis of these high-quality studies, thereby enabling better alignment with evidence-based practices in clinical decision-making.

Key words: Cerebrovascular disease; Ischemic stroke; Reperfusion therapy; Secondary prevention; Clinical research

摘要： 2025年，脑血管病临床研究在挑战与机遇中持续前行。全球研究者在缺血性卒中再灌注治疗边界拓展、辅助治疗策略优化及精准化二级预防等方面开展了大量探索。尽管神经保护、中等血管闭塞血管内治疗、康复治疗等领域的研究遭遇了阴性结果的考验，但再灌注治疗辅助治疗及晚时间窗溶栓等方面的突破性进展仍为脑血管病的临床实践注入了强劲动力。本文对2025年脑血管病领域的关键临床研究进行梳理与解读，旨在通过总结这些高质量研究，帮助读者了解学术前沿，把握学科发展脉搏，并帮助临床医师在卒中的诊疗中更好地遵循循证证据进行决策。

关键词: 脑血管病; 缺血性卒中; 再灌注治疗; 二级预防; 临床研究

CLC Number:

XIONG Yunyun, LU Zhengzhao, MA Ying, SHAN Dawei, WU Na, HAO Manjun, MA Yujie, WU Shuangzhe, LI Zhixin, SHEN Kejia, TANG Yizhe, WANG Yongjun. Highlights in Stroke in 2025[J]. Chinese Journal of Stroke, 2026, 21(1): 1-23.

熊云云, 路正钊, 马瑛, 单大卫, 吴娜, 郝曼均, 马宇洁, 武双喆, 李祉馨, 沈柯佳, 唐奕哲, 王拥军. 卒中：回眸2025[J]. 中国卒中杂志, 2026, 21(1): 1-23.

References

[1] SATTLER R，XIONG Z，LU W Y，et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein[J]. Science，1999，284（5421）：1845-1848.
[2] COOK D J，TEVES L，TYMIANSKI M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain[J]. Nature，2012，483（7388）：213-217.
[3] HILL M D，GOYAL M，MENON B K，et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke（ESCAPE-NA1）：a multicentre，double-blind，randomised controlled trial[J]. Lancet，2020，395（10227）：878-887.
[4] HILL M D，GOYAL M，DEMCHUK A M，et al. Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis（ESCAPE-NEXT）：a multicentre，double-blind，randomised controlled trial[J]. Lancet，2025，405（10478）：560-570.
[5] CHRISTENSON J，HILL M D，SWARTZ R H，et al. Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset（FRONTIER）：a phase 2，multicentre，randomised，double-blind，placebo-controlled study[J]. Lancet，2025，405（10478）：571-582.
[6] TYMIANSKI M，HILL M D，GOYAL M，et al. Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window：a post-hoc meta-analysis of individual patient data from three randomised trials[J]. Lancet Neurol，2025，24（3）：208-217.
[7] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.
[8] ZI W J，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs. intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.
[9] SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs. with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.
[10] LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.
[11] MITCHELL P J，YAN B，CHURILOV L，et al. Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4.5 h of stroke onset：an open-label，blinded-endpoint，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：116-125.
[12] FISCHER U，KAESMACHER J，STRBIAN D，et al. Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke：an open-label，blinded-outcome，randomised non-inferiority trial[J]. Lancet，2022，400（10346）：104-115.
[13] WANG L Y，HAO M J，WU N，et al. Comprehensive review of tenecteplase for thrombolysis in acute ischemic stroke[J/OL]. J Am Heart Assoc，2024，13（9）：e031692[2025-12-20]. https://doi.org/10.1161/JAHA.123.031692.
[14] QIU Z M，LI F L，SANG H F，et al. Intravenous tenecteplase before thrombectomy in stroke[J]. N Engl J Med，2025，393（2）：139-150.
[15] MAJOIE C B，CAVALCANTE F，GRALLA J，et al. Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke：individual participant data meta-analysis of six randomised trials[J]. Lancet，2023，402（10406）：965-974.
[16] RENÚ A，MILLÁN M，SAN ROMÁN L，et al. Effect of intra-arterial alteplase vs. placebo following successful thrombectomy on functional outcomes in patients with large vessel occlusion acute ischemic stroke：the CHOICE randomized clinical trial[J]. JAMA，2022，327（9）：826-835.
[17] HUANG J C，YANG J，LIU C，et al. Intra-arterial tenecteplase following endovascular reperfusion for large vessel occlusion acute ischemic stroke：the POST-TNK randomized clinical trial[J]. JAMA，2025，333（7）：579-588.
[18] MIAO Z R，LUO G，SONG L G，et al. Intra-arterial tenecteplase for acute stroke after successful endovascular therapy：the ANGEL-TNK randomized clinical trial[J]. JAMA，2025，334（7）：582-591.
[19] LIU C，GUO C W，LI F L，et al. Intra-arterial urokinase after endovascular reperfusion for acute ischemic stroke：the POST-UK randomized clinical trial[J]. JAMA，2025，333（7）：589-598.
[20] YANG X G，HE X J，XU Y T，et al. Intra-arterial alteplase after successful endovascular reperfusion in acute stroke：the PEARL randomized clinical trial[J]. JAMA，2025，334（19）：1728-1739.
[21] HU W，TAO C R，WANG L，et al. Intra-arterial tenecteplase after successful endovascular recanalization in patients with acute posterior circulation arterial occlusion（ATTENTION-IA）：multicentre randomised controlled trial[J/OL]. BMJ，2025，388：e080489[2025-12-20]. https://doi.org/10.1136/bmj-2024-080489.
[22] RENNERT R C，WALI A R，STEINBERG J A，et al. Epidemiology，natural history，and clinical presentation of large vessel ischemic stroke[J/OL]. Neurosurgery，2019，85（suppl_1）：S4-S8[2025-12-20]. https://doi.org/10.1093/neuros/nyz042.
[23] MEINEL T R，KAESMACHER J，CHALOULOS-IAKOVIDIS P，et al. Mechanical thrombectomy for basilar artery occlusion：efficacy，outcomes，and futile recanalization in comparison with the anterior circulation[J]. J Neurointerv Surg，2019，11（12）：1174-1180.
[24] GOYAL M，MENON B K，VAN ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.
[25] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med，2018，378（1）：11-21.
[26] ALBERS G W，MARKS M P，KEMP S，et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging[J]. N Engl J Med，2018，378（8）：708-718.
[27] DULOQUIN G，GRABER M，GARNIER L，et al. Incidence of acute ischemic stroke with visible arterial occlusion：a population-based study（Dijon stroke registry）[J]. Stroke，2020，51（7）：2122-2130.
[28] SCHULZE-ZACHAU V，BREHM A，NTOULIAS N，et al. Incidence and outcome of perforations during medium vessel occlusion compared with large vessel occlusion thrombectomy[J]. J Neurointerv Surg，2024，16（8）：775-780.
[29] GOYAL M，KAPPELHOF M，MCDONOUGH R，et al. Secondary medium vessel occlusions：when clots move north[J]. Stroke，2021，52（3）：1147-1153.
[30] MENON B K，HILL M D，DAVALOS A，et al. Efficacy of endovascular thrombectomy in patients with M2 segment middle cerebral artery occlusions：meta-analysis of data from the HERMES collaboration[J]. J Neurointerv Surg，2019，11（11）：1065-1069.
[31] LOH E W，TOH K Z X，KWOK G Y R，et al. Endovascular therapy for acute ischemic stroke with distal medium vessel occlusion：a systematic review and meta-analysis[J/OL]. J Neurointerv Surg，2023，15（e3）：e452-e459[2025-12-20]. https://doi.org/10.1136/jnis-2022-019717.
[32] SABER H，DESAI S M，HAUSSEN D，et al. Endovascular therapy vs. medical management for patients with acute stroke with medium vessel occlusion in the anterior circulation[J/OL]. JAMA Netw Open，2022，5（10）：e2238154[2025-12-20]. https://doi.org/10.1001/jamanetworkopen.2022.38154.
[33] WANG J，QIAN J C，FAN L，et al. Efficacy and safety of mechanical thrombectomy for M2 segment of middle cerebral artery：a systematic review and meta-analysis[J]. J Neurol，2021，268（7）：2346-2354.
[34] GOYAL M，OSPEL J M，GANESH A，et al. Endovascular treatment of stroke due to medium-vessel occlusion[J]. N Engl J Med，2025，392（14）：1385-1395.
[35] PSYCHOGIOS M，BREHM A，RIBO M，et al. Endovascular treatment for stroke due to occlusion of medium or distal vessels[J]. N Engl J Med，2025，392（14）：1374-1384.
[36] CLARENÇON F，DURAND-ZALESKI I，PREMAT K，et al. Evaluation of mechanical thrombectomy in acute ischemic stroke related to a distal arterial occlusion：a randomized controlled trial[J]. Int J Stroke，2024，19（3）：367-372.
[37] MA H，CAMPBELL B C V，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med，2019，380（19）：1795-1803.
[38] ALBERS G W，JUMAA M，PURDON B，et al. Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection[J]. N Engl J Med，2024，390（8）：701-711.
[39] XIONG Y Y，CAMPBELL B C V，SCHWAMM L H，et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy[J]. N Engl J Med，2024，391（3）：203-212.
[40] WANG Z X，LI J M，WANG X Y，et al. Tenecteplase for acute ischemic stroke at 4.5 to 24 hours：a meta-analysis of randomized controlled trials[J]. Stroke，2026，57（1）：50-62.
[41] ZHOU Y，HE Y D，CAMPBELL B C V，et al. Alteplase for acute ischemic stroke at 4.5 to 24 hours：the HOPE randomized clinical trial[J]. JAMA，2025，334（9）：788-797.
[42] YAN S Q，ZHOU Y，LANSBERG M G，et al. Alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours[J]. N Engl J Med，2025，392（13）：1288-1296.
[43] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2025-12-20]. https://doi.org/10.1161/STR.0000000000000211.
[44] DONG Q，DONG Y，LIU L P，et al. The Chinese Stroke Association scientific statement：intravenous thrombolysis in acute ischaemic stroke[J]. Stroke Vasc Neurol，2017，2（3）：147-159.
[45] HACKE W，KASTE M，BLUHMKI E，et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med，2008，359（13）：1317-1329.
[46] ABUMIYA T，FITRIDGE R，MAZUR C，et al. Integrin αⅡbβ3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia[J]. Stroke，2000，31（6）：1402-1410.
[47] LIU J，SHI Q Y，SUN Y，et al. Efficacy of tirofiban administered at different time points after intravenous thrombolytic therapy with alteplase in patients with acute ischemic stroke[J]. J Stroke Cerebrovasc Dis，2019，28（4）：1126-1132.
[48] WU C J，SUN C H，WANG L J，et al. Low-dose tirofiban treatment improves neurological deterioration outcome after intravenous thrombolysis[J]. Stroke，2019，50（12）：3481-3487.
[49] LI W，LIN L，ZHANG M，et al. Safety and preliminary efficacy of early tirofiban treatment after alteplase in acute ischemic stroke patients[J]. Stroke，2016，47（10）：2649-2651.
[50] LIU R H，LIANG Z G，LI W，et al. Adding tirofiban on top of recombinant tissue plasminogen activator may improve clinical outcome in acute stroke patients[J]. J Stroke，2024，26（1）：121-124.
[51] TAO C R，LIU T L，CUI T，et al. Early tirofiban infusion after intravenous thrombolysis for stroke[J]. N Engl J Med，2025，393（12）：1191-1201.
[52] LI W L，QI Z F，MA Q F，et al. Normobaric hyperoxia combined with endovascular treatment for patients with acute ischemic stroke：a randomized controlled clinical trial[J/OL]. Neurology，2022，99（8）：e824-e834[2025-12-20]. https://doi.org/10.1212/WNL.0000000000200775.
[53] LI W L，LAN J，WEI M，et al. Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China（OPENS-2 trial）：a multicentre，randomised，single-blind，sham-controlled trial[J]. Lancet，2025，405（10477）：486-497.
[54] National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med，1995，333（24）：1581-1587.
[55] BERGE E，WHITELEY W，AUDEBERT H，et al. European Stroke Organisation（ESO）guidelines on intravenous thrombolysis for acute ischaemic stroke[J]. Eur Stroke J，2021，6（1）：1-62.
[56] SUMMERS D，LEONARD A，WENTWORTH D，et al. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient：a scientific statement from the American Heart Association[J]. Stroke，2009，40（8）：
2911-2944.
[57] FAIGLE R，BUTLER J，CARHUAPOMA J R，et al. Safety trial of low-intensity monitoring after thrombolysis：optimal post tPA-IV monitoring in ischemic stroke（OPTIMIST）[J]. Neurohospitalist，2020，10（1）：11-15.
[58] FAIGLE R，JOHNSON B，SUMMERS D，et al. Low-intensity monitoring after stroke thrombolysis during the COVID-19 pandemic[J]. Neurocrit Care，2020，33（2）：333-337.
[59] ANDERSON C S，SUMMERS D，OUYANG M L，et al. Safety and efficacy of low-intensity versus standard monitoring following intravenous thrombolytic treatment in patients with acute ischaemic stroke（OPTIMISTmain）：an international，pragmatic，stepped-wedge，cluster-randomised，controlled non-inferiority trial[J]. Lancet，2025，405（10493）：1909-1922.
[60] BARKAT M，ROY I，ANTONIOU S A，et al. Systematic review and network meta-analysis of treatment strategies for asymptomatic carotid disease[J/OL]. Sci Rep，2018，8：4458[2025-12-20]. https://doi.org/10.1038/s41598-018-22356-z.
[61] REIFF T，ECKSTEIN H H，MANSMANN U，et al. Carotid endarterectomy or stenting or best medical treatment alone for moderate-to-severe asymptomatic carotid artery stenosis：5-year results of a multicentre，randomised controlled trial[J]. Lancet Neurol，2022，21（10）：877-888.
[62] BROTT T G，HOWARD G，LAL B K，et al. Medical management and revascularization for asymptomatic carotid stenosis[J/OL]. N Engl J Med，2025[2025-12-20]. https://doi.org/10.1056/NEJMoa2508800.
[63] DONNERS S J A，VAN VELZEN T J，CHENG S F，et al. Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis（ECST-2）：2-year interim results of a multicentre randomised trial[J]. Lancet Neurol，2025，24（5）：389-399.
[64] ŠKOLOUDÍK D，HRBÁČ T，KOVÁŘ M，et al. Sonolysis during carotid endarterectomy：randomised controlled trial[J/OL]. BMJ，2025，388：e082750[2025-12-20]. https://doi.org/10.1136/bmj-2024-082750.
[65] OLDGREN J，ÅSBERG S，HIJAZI Z，et al. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation（TIMING）：a registry-based randomized controlled noninferiority study[J]. Circulation，2022，146（14）：1056-1066.
[66] RUFF C T，GIUGLIANO R P，BRAUNWALD E，et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation：a meta-analysis of randomised trials[J]. Lancet，2014，383（9921）：955-962.
[67] SEIFFGE D J，WERRING D J，PACIARONI M，et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation[J]. Lancet Neurol，2019，18（1）：117-126.
[68] SEIFFGE D J，CANCELLONI V，RÄBER L，et al. Secondary stroke prevention in people with atrial fibrillation：treatments and trials[J]. Lancet Neurol，2024，23（4）：404-417.
[69] PALAIODIMOU L，STEFANOU M I，KATSANOS A H，et al. Timing of oral anticoagulants initiation for atrial fibrillation after acute ischemic stroke：a systematic review and meta-analysis[J]. Eur Stroke J，2024，9（4）：885-895.
[70] DEHBI H M，FISCHER U，ÅSBERG S，et al. Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation：a systematic review and prospective individual participant data meta-analysis of randomised controlled trials（CATALYST）[J]. Lancet，2025，406（10498）：43-51.
[71] VELTKAMP R，KOROMPOKI E，HARVEY K H，et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation（PRESTIGE-AF）：a multicentre，open-label，randomised，phase 3 trial[J]. Lancet，2025，405（10482）：927-936.
[72] CRAMER S C. Drugs to enhance motor recovery after stroke[J]. Stroke，2015，46（10）：2998-3005.
[73] KUMAR A，KITAGO T. Pharmacological enhancement of stroke recovery[J/OL]. Curr Neurol Neurosci Rep，2019，19（7）：43[2025-12-20]. https://doi.org/10.1007/s11910-019-0959-2.
[74] KESER Z，FRANCISCO G E. Neuropharmacology of poststroke motor and speech recovery[J]. Phys Med Rehabil Clin N Am，2015，26（4）：671-689.
[75] VIALE L，CATOIRA N P，DI GIROLAMO G，et al. Pharmacotherapy and motor recovery after stroke[J]. Expert Rev Neurother，2018，18（1）：65-82.
[76] BERENDS H I，NIJLANT J M M，MOVIG K L L，et al. The clinical use of drugs influencing neurotransmitters in the brain to promote motor recovery after stroke；a systematic review[J]. Eur J Phys Rehabil Med，2009，45（4）：621-630.
[77] MCALLISTER T W. Polymorphisms in genes modulating the dopamine system：do they influence outcome and response to medication after traumatic brain injury？[J]. J Head Trauma Rehabil，2009，24（1）：65-68.
[78] TRITSCH N X，SABATINI B L. Dopaminergic modulation of synaptic transmission in cortex and striatum[J]. Neuron，2012，76（1）：33-50.
[79] ABE M，SCHAMBRA H，WASSERMANN E M，et al. Reward improves long-term retention of a motor memory through induction of offline memory gains[J]. Curr Biol，2011，21（7）：557-562.
[80] SCHEIDTMANN K，FRIES W，MÜLLER F，et al. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke：a prospective，randomised，double-blind study[J]. Lancet，2001，358（9284）：787-790.
[81] LOKK J，SALMAN ROGHANI R，DELBARI A. Effect of methylphenidate and/or levodopa coupled with physiotherapy on functional and motor recovery after stroke—a randomized，double-blind，placebo-controlled trial[J]. Acta Neurol Scand，2011，123（4）：266-273.
[82] ENGELTER S T，KAUFMANN J E，ZIETZ A，et al. Levodopa added to stroke rehabilitation：the ESTREL randomized clinical trial[J]. JAMA，2025，334（17）：1523-1532.